Cost-of-illness analysis. What room in health economics?

Cost-of-illness (COI) was the first economic evaluation technique used in the health field. The principal aim was to measure the economic burden of illness to society. Its usefulness as a decision-making tool has however been questioned since its inception. The main criticism came from welfare economists who rejected COIs because they were not grounded in welfare economics theory. Other attacks related to the use of the human capital approach (HCA) to evaluate morbidity and mortality costs since it was said that the HCA had nothing to do with the value people attach to their lives. Finally, objections were made that COI could not be of any help to decision makers and that other forms of economic evaluation (e.g. cost-effectiveness, cost-benefit analysis) would be much more useful to those taking decisions and ranking priorities. Conversely, it is here suggested that COI can be a good economic tool to inform decision makers if it is considered from another perspective. COI is a descriptive study that can provide information to support the political process as well as the management functions at different levels of the healthcare organisations. To do that, the design of the study must be innovative, capable of measuring the true cost to society; to estimate the main cost components and their incidence over total costs; to envisage the different subjects who bear the costs; to identify the actual clinical management of illness; and to explain cost variability. In order to reach these goals, COI need to be designed as observational bottom-up studies.

[1]  A. Mcguire,et al.  Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. , 2000, Health economics.

[2]  T. Hodgson,et al.  Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8(1987) 317-323). , 1989, Health policy.

[3]  Lex M Bouter,et al.  Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method , 1999, Pain.

[4]  Erzo F. P. Luttmer,et al.  The Cost of Diabetes , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[5]  K. Smith,et al.  Costs of mental illness in Britain. , 1996, Health policy.

[6]  Rice Dp Cost of illness studies: what is good about them? , 2000 .

[7]  G. Thornicroft,et al.  Utilisation and costs of community mental health services , 1998, British Journal of Psychiatry.

[8]  A. Ludbrook,et al.  Collecting unit cost data in multicentre studies , 2005, The European Journal of Health Economics.

[9]  Joseph S. Pliskin,et al.  The Economic Value of Changing Mortality Probabilities: A Decision-Theoretic Approach , 1980 .

[10]  P Carlsson,et al.  Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.

[11]  Rice Dp,et al.  Cost-of-illness studies: fact or fiction? , 1994 .

[12]  W. Brouwer,et al.  Decision makers' views on health care objectives and budget constraints: results from a pilot study. , 2004, Health policy.

[13]  Selma J. Mushkin,et al.  Health as an Investment , 1962, Journal of Political Economy.

[14]  M A Koopmanschap,et al.  Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.

[15]  S. Gerzeli,et al.  Direct and indirect costs of schizophrenia in community psychiatric services in Italy: The GISIES study , 2000 .

[16]  A. Bracco Gli studi di “cost of illness” in Italia: una review della letteratura , 2001 .

[17]  D. Torgerson,et al.  Cost of illness studies , 2000, BMJ : British Medical Journal.

[18]  B. Jönsson Cost-benefit analysis in public health and medical care , 1976 .

[19]  E. Quah,et al.  Cost-Benefit Analysis , 1972 .

[20]  Rice Dp,et al.  Estimating the cost of illness. , 1967 .

[21]  M. Drummond,et al.  Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  C. Gandolfo,et al.  The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation , 2005, Neurological Sciences.

[23]  M. Koopmanschap,et al.  THE VALUATION OF INFORMAL CARE IN ECONOMIC APPRAISAL , 1999, International Journal of Technology Assessment in Health Care.

[24]  C N Smart,et al.  The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. , 1980, American journal of public health.

[25]  R. Fabian,et al.  Valuing Health for Policy , 1994 .

[26]  E. Mishan Evaluation of Life and Limb: A Theoretical Approach , 1971, Journal of Political Economy.

[27]  J. Beecham,et al.  Costing services: ideals and reality , 1993 .

[28]  M A Koopmanschap,et al.  Towards a new approach for estimating indirect costs of disease. , 1992, Social science & medicine.

[29]  S. Glied,et al.  Estimating the indirect cost of illness: an assessment of the forgone earnings approach. , 1996, American journal of public health.

[30]  Rice Dp,et al.  The economic cost of illness revisited. , 1976 .

[31]  Bryan R. Luce,et al.  Cost-Benefit and Cost-Effectiveness Analysis in Health Care: Principles, Practice, and Potential , 1982 .

[32]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[33]  Thomas E. Borcherding,et al.  The Measurement of Economic and Social Performance , 1977, American Political Science Review.

[34]  Gary Fromm,et al.  The Sources of Economic Growth in the United States and the Alternatives Before Us. , 1963 .

[35]  J. Posnett,et al.  Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. , 1996, Health economics.

[36]  T. Hodgson,et al.  Cost-of-illness methodology: a guide to current practices and procedures. , 1982, The Milbank Memorial Fund quarterly. Health and society.

[37]  J. Olsen,et al.  Theory versus practice: a review of 'willingness-to-pay' in health and health care. , 2001, Health economics.

[38]  THE VALUE O F NONMARKET HOUSEHOLD PRODUCTION: OPPORTUNITY COST VERSUS MARKET COST ESTIMATES , 1978 .

[39]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[40]  C. Donaldson,et al.  Cost of illness studies: An aid to decision-making? , 1987 .

[41]  R. Gronau The Measurement of Output of the Nonmarket Sector: The Evaluation of Housewives' Time , 1973 .

[42]  A. Williams Economics of coronary artery bypass grafting. , 1985, British medical journal.

[43]  L. Levin,et al.  Cost-effectiveness of thrombolysis--a randomized study of intravenous rt-PA in suspected myocardial infarction. , 1992, European heart journal.

[44]  M. Johannesson,et al.  Economic evaluation in health care: is there a role for cost-benefit analysis? , 1991, Health policy.

[45]  William Sir Petty Political arithmetick, or, A discourse : concerning, the extent and value of lands, people, buildings ... , 1992 .

[46]  K. Henke,et al.  Cost of illness studies: no aid to decision making: Reply to Shiell et al. (Health Policy, 8 (1987) 317-323). , 1988, Health policy.

[47]  Michael Drummond,et al.  Studies in economic appraisal in health care , 1981 .

[48]  B. Lindgren Costs of illness in Sweden, 1964-1975 , 1981 .

[49]  J. Graf von der Schulenburg,et al.  The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. , 2000, Health policy.